Literature DB >> 21444610

Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Christopher W Cunningham1, Richard B Rothman, Thomas E Prisinzano.   

Abstract

Salvia divinorum is a perennial sage native to Oaxaca, Mexico, that has been used traditionally in divination rituals and as a treatment for the "semimagical" disease panzón de borrego. Because of the intense "out-of-body" experiences reported after inhalation of the pyrolized smoke, S. divinorum has been gaining popularity as a recreational hallucinogen, and the United States and several other countries have regulated its use. Early studies isolated the neoclerodane diterpene salvinorin A as the principal psychoactive constituent responsible for these hallucinogenic effects. Since the finding that salvinorin A exerts its potent psychotropic actions through the activation of KOP receptors, there has been much interest in elucidating the underlying mechanisms behind its effects. These effects are particularly remarkable, because 1) salvinorin A is the first reported non-nitrogenous opioid receptor agonist, and 2) its effects are not mediated by the 5-HT(2A) receptor, the classic target of hallucinogens such as lysergic acid diethylamide and mescaline. Rigorous investigation into the structural features of salvinorin A responsible for opioid receptor affinity and selectivity has produced numerous receptor probes, affinity labels, and tools for evaluating the biological processes responsible for its observed psychological effects. Salvinorin A has therapeutic potential as a treatment for pain, mood and personality disorders, substance abuse, and gastrointestinal disturbances, and suggests that nonalkaloids are potential scaffolds for drug development for aminergic G-protein coupled receptors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21444610      PMCID: PMC3082450          DOI: 10.1124/pr.110.003244

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  206 in total

Review 1.  The microbiological transformation of diterpenoids.

Authors:  J R Hanson
Journal:  Nat Prod Rep       Date:  1992-04       Impact factor: 13.423

2.  Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.

Authors:  C A Heidbreder; S Schenk; B Partridge; T S Shippenberg
Journal:  Synapse       Date:  1998-11       Impact factor: 2.562

3.  Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum.

Authors:  L J Valdés; H M Chang; D C Visger; M Koreeda
Journal:  Org Lett       Date:  2001-11-29       Impact factor: 6.005

4.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

5.  Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.).

Authors:  L J Valdés; J L Díaz; A G Paul
Journal:  J Ethnopharmacol       Date:  1983-05       Impact factor: 4.360

6.  Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study.

Authors:  A Mansour; L P Taylor; J L Fine; R C Thompson; M T Hoversten; H I Mosberg; S J Watson; H Akil
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

7.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

8.  The ventral pallidal projection to the mediodorsal thalamus: a study with fluorescent retrograde tracers and immunohistofluorescence.

Authors:  W S Young; G F Alheid; L Heimer
Journal:  J Neurosci       Date:  1984-06       Impact factor: 6.167

9.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

10.  Salvinorins D-F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A.

Authors:  Thomas A Munro; Mark A Rizzacasa
Journal:  J Nat Prod       Date:  2003-05       Impact factor: 4.050

View more
  42 in total

Review 1.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

Review 2.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

3.  Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.

Authors:  Anil Yilmaz; Rachel Saylor Crowley; Alexander M Sherwood; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2017-07-18       Impact factor: 4.050

4.  Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.

Authors:  Xiaomeng Xu; Shifan Ma; Zhiwei Feng; Guanxing Hu; Lirong Wang; Xiang-Qun Xie
Journal:  J Mol Graph Model       Date:  2016-08-08       Impact factor: 2.518

Review 5.  Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease.

Authors:  William C Motel; Andrew Coop; Christopher W Cunningham
Journal:  Mini Rev Med Chem       Date:  2013-03       Impact factor: 3.862

Review 6.  Neoclerodanes as atypical opioid receptor ligands.

Authors:  Thomas E Prisinzano
Journal:  J Med Chem       Date:  2013-04-18       Impact factor: 7.446

7.  Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons.

Authors:  Raehannah J Jamshidi; Blaine A Jacobs; Laura C Sullivan; Teresa A Chavera; Rachel M Saylor; Thomas E Prisinzano; William P Clarke; Kelly A Berg
Journal:  J Pharmacol Exp Ther       Date:  2015-08-21       Impact factor: 4.030

8.  Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace.

Authors:  Ryan Vandrey; Matthew W Johnson; Patrick S Johnson; Miral A Khalil
Journal:  Adolesc Psychiatry (Hilversum)       Date:  2013-04

Review 9.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

10.  Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.

Authors:  Prabhakar R Polepally; Kate White; Eyal Vardy; Bryan L Roth; Daneel Ferreira; Jordan K Zjawiony
Journal:  Bioorg Med Chem Lett       Date:  2013-04-04       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.